Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis
Trastuzumab (H) with chemotherapy benefits patients with HER2+ breast cancer (BC); however, we lack head-to-head pairwise assessment of survival or cardiotoxicity for specific combinations. We sought to identify optimal combinations.
We searched PubMed, updated October 2017, using keywords “Breast Neoplasms/drug therapy,” “Trastuzumab,” and “Clinical Trial” and searched Cochrane Library. Our search included randomized trials of adjuvant H plus chemotherapy for early-stage HER2+ BC, and excluding trials of neoadjuvant therapy or without data to obtain hazard ratios (HRs) for outcomes. Following PRISMA guidelines, one investigator did initial search; two others independently confirmed and extracted information; and consensus with another investigator resolved disagreements. Before gathering data, we set outcomes of overall survival (OS), event-free survival (EFS), and severe cardiac adverse events (SCAEs). Analyzing 6 trials and 13,621 patients, we made direct and indirect comparisons using network meta-analysis on HR for OS or EFS and on odds ratio (OR) for SCAE; ranked therapy was done based on outcomes using p scores.
Compared with anthracycline-cyclophosphamide with taxane (ACT), ACT with concurrent H (ACT+H) showed best OS (HR 0.63, 95% confidence interval [CI] 0.55, 0.72), followed by taxane and carboplatin (TC) with concurrent H (TC+H) (HR 0.77, 95% CI 0.59, 1) and ACT with sequential H (ACT-H) (HR 0.85, 95% CI 0.68, 1.05). Pairwise comparisons showed statistically significant OS benefit for ACT+H over others; similar results for EFS. TC+H showed statistically significant lower SCAE risk compared to ACT+H (OR 0.13, 95% CI 0.03, 0.61).
Concurrent H with ACT or TC showed most clinical benefit for early-stage HER2+ BC; TC+H had lowest cardiotoxicity.
KeywordsAnthracycline Carboplatin Cardiotoxicity Cyclophosphamide Overall survival Taxane
LeeAnn Chastain, BA, of the Department of Biostatistics at The University of Texas MD Anderson Cancer Center provided scientific editing services.
YS and LX have full access to all of the data in the study collected from literature, and take responsibility for the integrity of the data and accuracy of the data analysis. Study concept and design: YS, TF, NTU, and LX. Acquisition, analysis, or interpretation of data: YS, LX, TF, NF, JN, HZ, NTU, and DT. Drafting of the manuscript: YS, LX, and TF. Critical revision of the manuscript for important intellectual content: YS, LX, TF, NTU, DT, JN, and NF. Statistical analysis: LX, HZ, JN, and YS. Obtained funding: YS, JN, and NTU. Administrative, technical, or material support: NF, YS, and LX. Study supervision: YS and NTU.
This study was partially supported by MD Anderson Cancer Center Support Grant from NCI (Grant CA016672), which supports the Biostatistics Share Resource.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no competing interests.
- 1.Siegel RL, Miller KD, Jemal A. Cancer statistics (2016) CA Cancer J Clin 2016; 66(1):7–30Google Scholar
- 2.Hynes N, Stern DF (1994) The biology of ErbB-2/neu/HER-2 and its role in cancer. Biochim Biophys Acta 1198(2–3):165–184Google Scholar
- 3.Yarden Y, Sliwkowsk MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2(2):127–137Google Scholar
- 4.Slamon DJ, Clark GM, Wong SG et al (1987) Human breast cancer: correlation of relapse and survival with amplification of HER-2/neu oncogene. Science 235(4785):177–182Google Scholar
- 5.Slamon DJ, Goldophin W, Jones LA et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905):707–712Google Scholar
- 6.Arboleda MJ, Lyons JF, Kabbinavar FF et al (2003) Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 63(1):196–206Google Scholar
- 7.Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24(2):85–95Google Scholar
- 8.De Luca A, Carotenuto A, Rachiglio A et al (2008) The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 214(3):559–567Google Scholar
- 9.Feigin ME, Muthuswamy SK (2009) ErbB receptors and cell polarity: new pathways and paradigms for understanding cell migration and invasion. Exp Cell Res 315(4):707–716Google Scholar
- 10.Izumi Y, Xu L, di Tomaso E et al (2002) Tumour biology: herceptin acts as an antiangiogenic cocktail. Nature 416(6878):279–280Google Scholar
- 11.Marcotte R, Muller WJ (2008) Signal transduction in transgenic mouse models of human breast cancer—implications for human breast cancer. J Mammary Gland Biol Neoplasia 13(3):323–335Google Scholar
- 12.Pietras RJ, Arboleda J, Reese DM et al (1995) HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene 10(12):2435–2446Google Scholar
- 13.She QB, Chandarlapaty S, Ye Q et al (2008) Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling. PLoS ONE 3(8):e3065Google Scholar
- 14.Baselga J, Carbonell X, Castañeda-Soto NJ et al (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23(10):162–171Google Scholar
- 15.Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11):783–792Google Scholar
- 16.National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (2015) https://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed 5 Aug 2015
- 17.De Laurentiis M, Cancello G, D’Agostino D et al (2008) Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J Clin Oncol 26(1):44–53Google Scholar
- 18.Gandhi S, Fletcher GG, Eisen A et al (2015) Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline. Curr Oncol 22(Suppl 1):S82–S94Google Scholar
- 19.Tan-Chiu E, Yothers G, Romond E et al (2005) Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23(31):7811–7819Google Scholar
- 20.Perez EA, Romond EH, Suman VJ et al (2014) Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol 32(33):3744–3752Google Scholar
- 21.Romond EH, Jeong JH, Rastogi P et al (2012) Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 30(31):3792–3799Google Scholar
- 22.Perez EA, Suman VJ, Davidson NE et al (2011) Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol 29(34):4491–4497Google Scholar
- 23.Genentech. Herceptin (trastuzumab) development timeline. Genentech product information. https://www.gene.com/media/product-information/herceptin-development-timeline. Accessed 20 Oct 2017
- 24.Peto R, Davies C, Godwin J et al (2012) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet 379(9814):432–444Google Scholar
- 25.Blum JL, Flynn PJ, Yothers G et al (2017) Anthracyclines in early breast cancer: the ABC Trials—USOR 06–090, NSABP B-46-I/USOR 07132, NSABP B-49 (NRG Oncology). J Clin Oncol 35:2647–2655Google Scholar
- 26.Bafeta A, Trinquart L, Seror R, Ravaud P (2014) Reporting of results from network meta-analyses: methodological systematic review. BMJ 348:g1741Google Scholar
- 27.Neupane B, Richer D, Bonner AJ et al (2014) Network meta-analysis using R: a review of currently available automated packages. PLoS ONE 9(12):e115065Google Scholar
- 28.Zhang J, Carlin BP, Neaton JD et al (2014) Network meta-analysis of randomized clinical trials: reporting the proper summaries. Clin Trials 11(2):246–262Google Scholar
- 29.Tonin FS, Rotta I, Mendes AM, Pontarolo R (2017) Network meta-analysis: a technique to gather evidence from direct and indirect comparisons. Pharm Pract (Granada) 15(1):943Google Scholar
- 30.Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62(10):31–34Google Scholar
- 31.Joensuu H, Bono P, Kataja V et al (2009) Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. J Clin Oncol 27(34):5685–5692Google Scholar
- 32.Spielmann M, Roché H, Delozier T et al (2009) Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. J Clin Oncol 27(36):6129–6134Google Scholar
- 33.Slamon D, Eiermann W, Robert N et al (2011) Adjuvant trastuzumab in Her2-positive breast cancer. N Engl J Med 365(14):1273–1283Google Scholar
- 34.Cameron D, Piccart-Gebhart MJ, Gelber RD et al (2017) 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet 389(10075):1195–1205Google Scholar
- 35.Goldstein LJ, O’Neill A, Sparano JA et al (2008) Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol 26(25):4092–4099Google Scholar
- 36.Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352(22):2302–2313Google Scholar
- 37.Martín M, Seguí MA, Antón A et al (2010) Adjuvant docetaxel for high-risk, node-negative breast cancer. N Engl J Med 363(23):2200–2210Google Scholar
- 38.Higgins J, Green S. (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. the cochrane collaboration. https://www.cochrane-handbook.org.
- 39.Parmar MK, Torri V, Stewart L (1998) Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med 17(24):2815–2834. Erratum in Stat Med 2004; 23(11): 1817Google Scholar
- 40.Tierney JF, Stewart LA, Ghersi D et al (2007) Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8:16Google Scholar
- 41.Rücker G (2012) Network meta-analysis, electrical networks and graph theory. Res Synth Methods 3(4):312–324Google Scholar
- 42.Rücker G, Schwarzer G (2015) Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol 15:58Google Scholar
- 43.Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327(7414):557–560Google Scholar
- 44.Krahn U, Binder H, König J (2013) A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol 13:35Google Scholar
- 45.Jackson D, White IR, Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31(29):3805–3820Google Scholar
- 46.Goldhirsch A, Gelber RD, Piccart-Gebhart MJ et al (2013) 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. Lancet 382(9897):1021–1028Google Scholar
- 47.Clinical Trials.gov. Trial Identifier: NCT00021255. Cancer International Research Group. https://clinicaltrials.gov/ct2/show/NCT00021255. Accessed 30 Nov 2017
- 48.Dahabreh IJ, Linardou H, Siannis F et al (2008) Trastuzumab in the adjuvant treatment of early stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 13(6):620–630Google Scholar
- 49.Viani GA, Afonso SL, Stefano EJ et al (2007) Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 7:153Google Scholar
- 50.Nagayama A, Hayashida T, Jinno H et al (2014) Comparative effectiveness of neoadjuvant therapy for HER2–positive breast cancer: a network meta-analysis. J Natl Cancer Inst 106(9):pii:dju203Google Scholar
- 51.Chavez-MacGregor M, Zhang N, Buchholz TA et al (2013) Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 31(33):4222–4228Google Scholar
- 52.Eiermann W, Pienkowski T, Crown J et al (2011) Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial. J Clin Oncol 29(29):3877–3884Google Scholar
- 53.Gradishar WG, Anderson BO, Blair SL et al (2014) Breast cancer version 3.2014. J Natl Compr Cancer Netw 12(4):542–590Google Scholar
- 54.Ganz PA, Land SR, Geyer CE et al (2009) NSABP B-30: definitive analysis of quality of life (QOL) and menstrual history (MH) outcomes from a randomized trial evaluating different schedules and combinations of adjuvant therapy containing doxorubicin, docetaxel and cyclophosphamide in women with operable, node-positive breast cancer. Cancer Res 69(2 Suppl):Abst 76Google Scholar
- 55.Baselga J, Cortés J, Kim SB et al (2012) Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 366(2):109–119Google Scholar
- 56.Minckwitz G, Procter MJ et al (2017) Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med 377:122–131Google Scholar
- 57.Moreno-Aspitia A, Holmes EM et al (2017) Updated results from the phase III ALTTO trial (BIG 2–06; NCCTG (Alliance) N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L) or their combination (L + T) in the adjuvant treatment of HER2-positive early breast cancer. J Clin Oncol 35:15_suppl, 502–502Google Scholar